How did Vertex Pharmaceuticals Incorporated's revenue change from 2022 to 2023?

Vertex Pharmaceuticals Incorporated revenue grew from $8.9B in 2022 to $9.9B in 2023, a change of 10.4%.

Was 2023 Vertex Pharmaceuticals Incorporated's best revenue year?

No. Vertex Pharmaceuticals Incorporated's highest recorded revenue year was 2024 at $10.7B. In 2023, Vertex Pharmaceuticals Incorporated reported $9.9B.

What was Vertex Pharmaceuticals Incorporated's highest ever annual revenue?

Vertex Pharmaceuticals Incorporated's highest ever annual revenue was $10.7B recorded in fiscal year 2024.

Vertex Pharmaceuticals Incorporated

BiotechnologyFounded 1989

Reviewed by Swet Parvadiya

Last reviewed: June 2026

Explore Vertex Pharmaceuticals Incorporated

Core profile pages, annual revenue records, and related research hubs for this company.

Vertex Pharmaceuticals Incorporated

BiotechnologyFounded 1989

Reviewed by Swet Parvadiya

Last reviewed: June 2026

Annual Revenue

Vertex Pharmaceuticals Incorporated Revenue in 2023

Q: What was Vertex Pharmaceuticals Incorporated's revenue in 2023?

Vertex Pharmaceuticals Incorporated reported $9.9B in revenue for fiscal year 2023. This represents a +10.4% change compared to 2022. Revenue climbed about 10.4% to $9.86 billion in 2023, the year the FDA approved Casgevy, the first CRISPR-Cas9 gene-edited therapy, and Vertex acquired Alpine Immune Sciences for $4.9 billion.

FY2023 Revenue

$9.9B

▲ 10.4% vs FY2022 ($8.9B)

Source: Annual report / company filing

Vertex Pharmaceuticals Incorporated reported $9.9B in revenue for fiscal year 2023. This represents a growth of 10.4% compared to the 2022 figure of $8.9B. In 2024, revenue increased to $10.7B.

Revenue climbed about 10.4% to $9.86 billion in 2023, the year the FDA approved Casgevy, the first CRISPR-Cas9 gene-edited therapy, and Vertex acquired Alpine Immune Sciences for $4.9 billion.

Revenue by Year

FY2024 FY2023 FY2022

Vertex Pharmaceuticals Incorporated Annual Revenue History

Year	Revenue	Net Income	YoY Change
FY2024	$10.7B	$3.8B	+8.2%
FY2023	$9.9B	—	+10.4%
FY2022	$8.9B	—	—

Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.

← Previous year

FY2022: $8.9B

Next year →

FY2024: $10.7B

Explore Vertex Pharmaceuticals Incorporated

Core profile pages, annual revenue records, and related research hubs for this company.